Cargando…

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Liting, Zhang, Haijun, Chen, Baoan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332892/ https://www.ncbi.nlm.nih.gov/pubmed/28261342 http://dx.doi.org/10.7150/jca.17144

Ejemplares similares

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
por: Kong, Xianbin, et al.
Publicado: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
por: Guo, Liting, et al.
Publicado: (2015)

Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor
por: Li, Qiao, et al.
Publicado: (2016)

Programmed Cell Death Protein‐1 (PD‐1)‐Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World
por: Cui, Hanzhi, et al.
Publicado: (2020)

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
por: Fessas, Petros, et al.
Publicado: (2017)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Anti–Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis()
por: Chen, Ran, et al.
Publicado: (2016)

Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor
por: Shimatani, Kimihiro, et al.
Publicado: (2018)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

Cancer immunotherapies targeting the PD-1 signaling pathway
por: Iwai, Yoshiko, et al.
Publicado: (2017)

Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis
por: Levy, Dylan A., et al.
Publicado: (2022)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
por: Inoue, Yusuke, et al.
Publicado: (2020)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
por: Abdin, Shifaa M., et al.
Publicado: (2018)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
por: Shen, John, et al.
Publicado: (2018)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
por: Bari, Shahla, et al.
Publicado: (2019)

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2018)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

The role of exosomal PD-L1 in tumor progression and immunotherapy
por: Xie, Feiting, et al.
Publicado: (2019)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma
por: Griffin, Liezel L., et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Onychopathy Induced by Nivolumab: A Targeted Immunotherapy
por: Zahoor, Fatima, et al.
Publicado: (2022)

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
por: Imakita, Takuma, et al.
Publicado: (2023)

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Bacteria-mediated tumor immunotherapy via photothermally-programmed PD1 expression
por: Xu, Wenxuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qjqpn34f3s8ahadbh86j6buhb2